XFOR Stock Overview
A late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
X4 Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.02 |
52 Week High | US$2.13 |
52 Week Low | US$0.57 |
Beta | 0.40 |
1 Month Change | 9.87% |
3 Month Change | 5.07% |
1 Year Change | -52.78% |
3 Year Change | -86.22% |
5 Year Change | -93.16% |
Change since IPO | -93.29% |
Recent News & Updates
Recent updates
Is X4 Pharmaceuticals (NASDAQ:XFOR) Weighed On By Its Debt Load?
Mar 26Is X4 Pharmaceuticals (NASDAQ:XFOR) A Risky Investment?
Apr 19Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Too Much Debt?
Oct 07X4 Pharmaceuticals: Upcoming Catalysts
Sep 19X4 Pharma to focus resources on lead drug candidate, cut workforce by about 20%
Jul 20X4 Pharmaceuticals to raise $55M in stock and warrants offering, debt facility amended
Jul 01X4 Pharma: Late Stage Nanocap Targeting Rare Diseases
Aug 03Is X4 Pharmaceuticals (NASDAQ:XFOR) Using Debt Sensibly?
Jun 22X4 Pharmaceuticals EPS misses by $0.44
May 06How Many X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Do Institutions Own?
Mar 16X4 Pharmaceuticals EPS misses by $0.12
Nov 05Shareholder Returns
XFOR | US Biotechs | US Market | |
---|---|---|---|
7D | -1.9% | -0.1% | 1.0% |
1Y | -52.8% | 7.1% | 20.8% |
Return vs Industry: XFOR underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: XFOR underperformed the US Market which returned 20.8% over the past year.
Price Volatility
XFOR volatility | |
---|---|
XFOR Average Weekly Movement | 13.6% |
Biotechs Industry Average Movement | 10.3% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.4% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: XFOR's share price has been volatile over the past 3 months.
Volatility Over Time: XFOR's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 116 | Paula Ragan | www.x4pharma.com |
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases.
X4 Pharmaceuticals, Inc. Fundamentals Summary
XFOR fundamental statistics | |
---|---|
Market cap | US$171.30m |
Earnings (TTM) | -US$128.91m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.3x
P/E RatioIs XFOR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
XFOR income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$128.91m |
Earnings | -US$128.91m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.77 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 5,291.9% |
How did XFOR perform over the long term?
See historical performance and comparison